Tags

Type your tag names separated by a space and hit enter

Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.
Aliment Pharmacol Ther 2005; 22(11-12):1157-60AP

Abstract

BACKGROUND

Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exist on small intestinal bacterial overgrowth prevalence in a significant population of healthy non-irritable bowel syndrome subjects.

AIM

To assess the prevalence of small intestinal bacterial overgrowth by glucose breath test in patients with irritable bowel syndrome symptoms with respect to a consistent control group.

METHODS

Consecutive patients with irritable bowel syndrome according to Rome II criteria were enrolled. The control population consisted of 102 sex- and age-matched healthy subjects without irritable bowel syndrome symptoms. All subjects underwent glucose breath test. A peak of H2 values >10 p.p.m above the basal value after 50 g of glucose ingestion was considered suggestive of small intestinal bacterial overgrowth.

RESULTS

A total of 65 irritable bowel syndrome patients and 102 healthy controls were enrolled. Positivity to glucose breath test was found in 31% of irritable bowel syndrome patients with respect to 4% in the control group, the difference between groups resulting statistically significant (OR: 2.65; 95% CI: 3.5-33.7, P < 0.00001).

CONCLUSIONS

The present case-control study showed an epidemiological association between irritable bowel syndrome and small intestinal bacterial overgrowth. Placebo-controlled small intestinal bacterial overgrowth-eradication studies are necessary to clarify the real impact of small intestinal bacterial overgrowth on irritable bowel syndrome symptoms.

Authors+Show Affiliations

Internal Medicine Department, Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16305730

Citation

Lupascu, A, et al. "Hydrogen Glucose Breath Test to Detect Small Intestinal Bacterial Overgrowth: a Prevalence Case-control Study in Irritable Bowel Syndrome." Alimentary Pharmacology & Therapeutics, vol. 22, no. 11-12, 2005, pp. 1157-60.
Lupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther. 2005;22(11-12):1157-60.
Lupascu, A., Gabrielli, M., Lauritano, E. C., Scarpellini, E., Santoliquido, A., Cammarota, G., ... Gasbarrini, A. (2005). Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 22(11-12), pp. 1157-60.
Lupascu A, et al. Hydrogen Glucose Breath Test to Detect Small Intestinal Bacterial Overgrowth: a Prevalence Case-control Study in Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2005;22(11-12):1157-60. PubMed PMID: 16305730.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. AU - Lupascu,A, AU - Gabrielli,M, AU - Lauritano,E C, AU - Scarpellini,E, AU - Santoliquido,A, AU - Cammarota,G, AU - Flore,R, AU - Tondi,P, AU - Pola,P, AU - Gasbarrini,G, AU - Gasbarrini,A, PY - 2005/11/25/pubmed PY - 2006/4/4/medline PY - 2005/11/25/entrez SP - 1157 EP - 60 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 22 IS - 11-12 N2 - BACKGROUND: Studies assessing the prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome gave contrasting results. Differences in criteria to define irritable bowel syndrome patients and methods to assess small intestinal bacterial overgrowth may explain different results. Moreover, no data exist on small intestinal bacterial overgrowth prevalence in a significant population of healthy non-irritable bowel syndrome subjects. AIM: To assess the prevalence of small intestinal bacterial overgrowth by glucose breath test in patients with irritable bowel syndrome symptoms with respect to a consistent control group. METHODS: Consecutive patients with irritable bowel syndrome according to Rome II criteria were enrolled. The control population consisted of 102 sex- and age-matched healthy subjects without irritable bowel syndrome symptoms. All subjects underwent glucose breath test. A peak of H2 values >10 p.p.m above the basal value after 50 g of glucose ingestion was considered suggestive of small intestinal bacterial overgrowth. RESULTS: A total of 65 irritable bowel syndrome patients and 102 healthy controls were enrolled. Positivity to glucose breath test was found in 31% of irritable bowel syndrome patients with respect to 4% in the control group, the difference between groups resulting statistically significant (OR: 2.65; 95% CI: 3.5-33.7, P < 0.00001). CONCLUSIONS: The present case-control study showed an epidemiological association between irritable bowel syndrome and small intestinal bacterial overgrowth. Placebo-controlled small intestinal bacterial overgrowth-eradication studies are necessary to clarify the real impact of small intestinal bacterial overgrowth on irritable bowel syndrome symptoms. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/16305730/Hydrogen_glucose_breath_test_to_detect_small_intestinal_bacterial_overgrowth:_a_prevalence_case_control_study_in_irritable_bowel_syndrome_ L2 - https://doi.org/10.1111/j.1365-2036.2005.02690.x DB - PRIME DP - Unbound Medicine ER -